3 days popular7 days popular1 month popular3 months popular

Switched before birth: Study shows protein creates tumor-fighting cells

Revealing a biological combat strategy worthy of a five-star general, researchers from Houston Methodist Hospital, University of Chicago and Cornell University have shown how a cell surface receptor–a specialized protein which communicates signals between a cell and the outside world–can mobilize immune cells to attack, rather than protect, malignant tumors. The researchers report their findings [...]

Researchers uncover pediatric brain tumor cells using precision medicine that could lead to improved treatment

International collaborators, including researchers from Children’s National Health System, have unraveled profiles in the genetic makeup of tumor cells in children that could more readily identify their growth and response to treatment, offering the possibility of better, more precise therapy. While there has been a longtime belief that results from single biopsies can represent entire [...]

Pancreas cancer spread from multiple types of wayward cells

Penn animal study has implications for better drug design, ‘unprecedented window’ into tumor evolution Tumor cells associated with pancreatic cancer often behave like communities by working with each other to increase tumor spread and growth to different organs. Groups of these cancer cells are better than single cancer cells in driving tumor spread, according to [...]

Combination therapy may be more effective against the most common ovarian cancer

Research reveals how ‘time bomb’ cells evade chemotherapy and cause tumors to recur High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but why it so frequently comes back after treatment has been a medical mystery. Now a team of UCLA researchers has discovered that a subset of tumor cells that don’t [...]

MEDI4736 combined with tremelimumab results in acceptable toxicity in NSCLC patients

Results from a phase 1b study of MEDI4736 and tremelimumab show manageable toxicity and clinical activity in advanced NSCLC patients with and without PD-L1 tumor expression Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and [...]